Ultrasound vs Veinviewer in Patients With Difficulty IV Access

November 8, 2025 updated by: Quincy Tran, University of Maryland, Baltimore

Preventing Delay of Care in Patient With Difficult IV Access: A Randomized Trial of ED Intervention

Patients with difficulty intravenous access frequently have delay of care in emergency departments because Emergency Department (ED) personnel could not establish intravenous (IV) access for diagnostic blood test or treatment. The ultrasound machine or near-infrared devices have been used to improve this situation but no study has ever compared which machine is more efficient. This study is designed to investigate whether the ultrasound or Vein Viewer, which is a near-infrared device, is more efficient.

Study Overview

Status

Withdrawn

Intervention / Treatment

Detailed Description

Intravenous (IV) access is important for patient care in emergency medicine as an estimate of 78% of ED patients would require more than 3 ED resources such as blood tests, medication, contrast, fluid. Care for patients with difficult intravenous access (DIVA) could be significantly delayed as it may take up to 120 minutes to establish IV access in patients with severe DIVA. Many solutions for DIVA had also been established to avoid central venous catheter insertion, including using ultrasound or near-infrared imaging systems for peripheral IV insertion.

Using ultrasound in the ED has been shown to decrease the rate of central venous catheters (CVC) insertion. However, the results from ultrasound-guided peripheral IV insertion (USGPIV) have been mixed. Among patients with DIVA, Costantino reported USGPIV required less time to successful first cannulation and fewer punctures comparing to traditional approach of landmark and palpation. However, other studies showed that USGPIV did not improve successful first attempts comparing to traditional IV insertion, and may have taken same or even longer time to successfully establish IV. USGPIV success rate requires more training for nurses and ED technicians as it is operator - dependent.

Patients have difficulty with IV access because their veins' clinical accessibility is low, for example, they are less visible or less palpable. The near-infrared imaging devices, such as Christie Digital's VeinViewer, improve this situation by using infra-red lights to make veins visible to the eyes.

Compared with routine IV insertion, near-Infra red imaging devices have been shown to increase first successful attempts and in less time in children with DIVA and improved visualization of peripheral veins. However, it did not show higher rate of successful attempts nor faster time in non-selected adults.

The efficacy of these near-infrared devices has not been established among adult patients with DIVA.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21201
        • University of Maryland Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients who fail inspections for visible or palpable veins or
  • Patients who request Ultrasound guided peripheral IV (USGPIV)
  • patients who are oriented to self (correct last name, first name), place (correct name of hospital), time (correct day of week or month of year) and person (correct name of current president)

Exclusion Criteria:

  • Patients < 18 years of age
  • Patients with hemodynamically instability requiring rapid central access.
  • Patients with impaired cognition and not able to consent, these patients are :

    • Clinically intoxicated patients, as defined by primary team.
    • Patients who family reported as "confused", "confusion", "altered mental status."
    • Patients who is not oriented x 4 as above
  • Patients who do not speak English.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Zonare
108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
Experimental: Veinviewer
108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Operator's time
Time Frame: up to 40 minutes
time from equipment-in-room to successful aspiration of 3ml of blood
up to 40 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of first successful attempts
Time Frame: 40 minutes
operators have up to 40 minutes or 3 attempts.
40 minutes
Number of failures
Time Frame: 40 minutes
operators have up to 40 minutes or 3 attempts prior to patients crossing over or requiring a rescue modality
40 minutes
IV size
Time Frame: 40 minutes
operators have up to 40 minutes or 3 attempts to establish IV from 18 to 24 gauge
40 minutes
Patient satisfaction
Time Frame: up to 40 minutes
after completion of IV cannulation
up to 40 minutes
Patient's perception of pain
Time Frame: up to 40 minutes
after completion of IV cannulation
up to 40 minutes
ED length of stay
Time Frame: 24 hours
Length of stay for discharged patients.
24 hours
hospital length of stay for admitted patient
Time Frame: 30 days
Length of stay for admitted patients
30 days
Cannulation time
Time Frame: 40 minutes
time from applying tourniquet to successful aspiration of 3ml of blood.
40 minutes
Number of failure to cannulate
Time Frame: 40 minutes
operators have up to 40 minutes or 3 attempts.
40 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Quincy Tran, MD, PhD, University of Maryland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2016

Primary Completion (Actual)

May 5, 2025

Study Completion (Actual)

May 5, 2025

Study Registration Dates

First Submitted

November 4, 2015

First Submitted That Met QC Criteria

November 27, 2015

First Posted (Estimated)

December 1, 2015

Study Record Updates

Last Update Posted (Estimated)

November 12, 2025

Last Update Submitted That Met QC Criteria

November 8, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • HP-00065438

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vascular Access Complication

Clinical Trials on Zonare

Subscribe